FibroBiologics, Inc. Common Stock Cash Flow-to-Debt Ratio
FibroBiologics, Inc. Common Stock cash flow-to-debt ratio. FibroBiologics, Inc. Common Stock (FBLG) has a Cash Flow-to-Debt Ratio of -0.46x as of September 2025, meaning its operating cash flow of $-3.97 Million could theoretically repay 0% of its total liabilities ($8.62 Million) in one year. Check FBLG cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of FibroBiologics, Inc. Common Stock (2022–2025)
Cash flow-to-debt ratio of FibroBiologics, Inc. Common Stock from 2022 to 2025. Historical debt coverage capacity for FibroBiologics, Inc. Common Stock across 4 annual periods. Also explore FibroBiologics, Inc. Common Stock net asset momentum to track the company's year-over-year net asset growth rate.
FibroBiologics, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2022–2025)
FibroBiologics, Inc. Common Stock cash flow-to-debt ratio by year from 2022 to 2025. Year-by-year debt coverage analysis for FibroBiologics, Inc. Common Stock. For the full cash flow conversion analysis, see FibroBiologics, Inc. Common Stock cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.87x | $-11.90 Million | $13.71 Million | ▼ -43.3% |
| 2024 | -0.61x | $-6.40 Million | $10.57 Million | ▼ -31.4% |
| 2023 | -0.46x | $-4.07 Million | $8.82 Million | ▲ +42.5% |
| 2022 | -0.80x | $-1.41 Million | $1.76 Million | — |